China's State Administration for Market Regulation (SAMR) has released the draft Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (Draft Guidelines) for public comment. The Draft Guidelines,...more
12/23/2024
/ Anti-Bribery ,
Bribery ,
China ,
Comment Period ,
Draft Guidance ,
Healthcare ,
Life Sciences ,
Medical Devices ,
Pharmaceutical Industry ,
Regulatory Agenda ,
State Administration for Market Regulation (SAMR)